Healthcare

💊 Glucosamine Warning for People With Early Cognitive Decline - A 65,000-patient Nature Metabolism analysis links glucosamine use to a 25% higher likelihood of Alzheimer's progression in those with mild cognitive impairment, a finding with immediate clinical relevance for one of the most widely used supplements in older adults. 💪 Retatrutide Sets a New Ceiling for What Metabolic Drugs Can Achieve - Lilly's triple agonist delivered an average 71-pound weight loss in Phase 3 while also reducing arthritis pain, establishing the drug as a potential platform therapy across metabolic and musculoskeletal aging simultaneously. 🥗 Oral GLP-1 Drugs Enter Their Most Competitive Phase Yet - Orforglipron beat oral semaglutide in a Lancet head-to-head trial and AstraZeneca's elecoglipron advanced to Phase 3 on 10.5% weight loss data, creating a three-way race for the oral metabolic drug market. 🤖 SLAMF6 Could Unlock Immunotherapy for Patients Who Have Run Out of Options - A Nature study identifies a self-activating T cell brake that suppresses immunity independently of tumors, opening a new class of cancer treatment targets for patients most likely to fail existing checkpoint inhibitors. ❤️ Sleep Apnea Cardiovascular Risk Now Has a Gut Target - The bile acid receptor FXR, operating through gut microbiome signaling, is now identified as a mediator of arterial plaque buildup during sleep apnea, a finding that may eventually lead to gut-directed prevention strategies for cardiovascular disease in this high-risk population.